In the Englander Institute for Precision Medicine (EIPM), we are changing the face of how we diagnose, treat, and care for patients using a personalized approach and genomic sequencing data. Some of the most serious diseases can be traced in our genome. For these diseases, in EIPM we aim to deliver more effective treatments by identifying and characterizing genomic changes underlying genetic-based ailments. In EIPM we collaborate with clinical departments of WCM and NYP to provide a comprehensive interpretation of patient genomes and act as a permanent resource for our clinicians to make effective use of genomic data to optimize patient care. To this effort, we are channeling our efforts towards developing therapies where genomic data contribute significantly to the clinical result and offer hope for transforming health care.
These innovative research areas include:
- Prostate, Bladder and Kidney cancer
- Hematologic Malignancies
- Gastrointestinal Oncology
- Endocrine Cancers
The EIPM laboratories are dedicated to bench-side research that will lead to new bedside therapies. To this effort, we have developed an Organoid Lab and an Innovation Lab that is going to move forward our future research.
Given that each tumor has its own unique molecular identity, here at EIPM, we have been using organoids as models to make more precise diagnoses and develop more effective treatments.
The EIPM provides the technology to procure, sequence and analyze genetic information in form of big data. Our researchers use a number of powerful in-house developed bioinformatics tools such as customized software programs, AI & machine learning and new age data visualization to fully interpret, visualize and understand complex next-generation sequence data, in order to develop new therapies and drug combinations.
All the Projects, Featured Publications, Press coverage and collaborators for the AI projects of the EIPM are available in the AI page.
In EIPM, we use Data Visualization to better assist to patient diagnosis and drug discoveries.
The research initiative at the EIPM at WCM brings together multitalented and motivated physician-scientists and researchers from within Weill Cornell Medicine at institutions like the Sandra and Edward Meyer Cancer Center to investigators around the world that specialize in various different fields including medicine, computational biology, genomics, and biomedicine to target some of the most formidable health challenges. This multidisciplinary approach is critical to advancing treatment and speeding the handoff from discovery to clinical implementation. Our researchers are pushing scientific discoveries forward and speeding breakthroughs made in the laboratory directly to the patient’s bedside.